NYSEAMERICAN:ASXC Asensus Surgical (ASXC) Stock Price, News & Analysis $0.35 0.00 (0.00%) As of 08/22/2024 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipBuy This Stock About Asensus Surgical Stock (NYSEAMERICAN:ASXC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Asensus Surgical alerts:Sign Up Key Stats Today's Range$0.35▼$0.3550-Day Range$0.35▼$0.3552-Week Range$0.17▼$0.40VolumeN/AAverage Volume2.03 million shsMarket Capitalization$94.74 millionP/E RatioN/ADividend YieldN/APrice Target$0.35Consensus RatingHold Company OverviewAsensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.Read More… Receive ASXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter. Email Address ASXC Stock News HeadlinesAsensus Surgical Announces Closing of Acquisition by KARL STORZAugust 22, 2024 | globenewswire.comDurham public company staves off potential bankruptcy, will be acquiredAugust 21, 2024 | bizjournals.comWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, May 14. And as Fortune has written, this IPO is “larger than any IPO valuation in history”… May 12, 2025 | Paradigm Press (Ad)Durham company could face bankruptcy if $95M sale failsAugust 15, 2024 | bizjournals.comBiggest stock movers today: NU, K, and moreAugust 14, 2024 | msn.comAsensus says it expects to file for bankruptcy if merger vote failsAugust 13, 2024 | msn.comAsensus Surgical, Inc. (ASXC) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comAsensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024August 13, 2024 | finance.yahoo.comSee More Headlines ASXC Stock Analysis - Frequently Asked Questions How have ASXC shares performed this year? Asensus Surgical's stock was trading at $0.3479 at the beginning of 2025. Since then, ASXC shares have increased by 0.0% and is now trading at $0.3479. View the best growth stocks for 2025 here. How were Asensus Surgical's earnings last quarter? Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company earned $2.57 million during the quarter, compared to the consensus estimate of $1.02 million. Asensus Surgical had a negative net margin of 902.25% and a negative trailing twelve-month return on equity of 184.10%. How do I buy shares of Asensus Surgical? Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Asensus Surgical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Asensus Surgical investors own include Digital Turbine (APPS), CrowdStrike (CRWD), ChargePoint (CHPT), SoFi Technologies (SOFI) and Tesla (TSLA). Company Calendar Last Earnings11/03/2021Today5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:ASXC CIKN/A Webwww.asensus.com Phone(919) 765-8400Fax919-765-8459Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$0.35 High Stock Price Target$0.35 Low Stock Price Target$0.35 Potential Upside/Downside+0.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,430,000.00 Net Margins-902.25% Pretax Margin-899.16% Return on Equity-184.10% Return on Assets-114.75% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio0.69 Sales & Book Value Annual Sales$8.58 million Price / Sales11.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book2.68Miscellaneous Outstanding Shares272,330,000Free Float264,516,000Market Cap$94.74 million OptionableNot Optionable Beta1.37 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NYSEAMERICAN:ASXC) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrop these 5 stocks now!You think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Asensus Surgical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Asensus Surgical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.